Aprea Therapeutics Inc
Veridion Score
Composite trend over time
Why is APRE moving today?
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for APRE.
APRE insider activity
Aprea Therapeutics Inc
2 insiders bought in the last 90 days
Net buying: $211K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | 2026-03-31 | Hamill John P. | Insider | buy | $0.81 | 30,978 | 30,978 | $25K | SEC Form 4 |
| 2026-04-01 | 2026-03-31 | Peters Richard | Insider | buy | $0.81 | 123,915 | 123,915 | $100K | SEC Form 4 |
| 2026-02-02 | 2026-01-30 | Gilad Oren | Insider | buy | $0.89 | 28,100 | 373,720 | $25K | SEC Form 4 |
| 2026-02-02 | 2026-01-30 | Hamill John P. | Insider | buy | $0.89 | 5,700 | 33,433 | $5K | SEC Form 4 |
| 2025-12-11 | 2025-12-10 | Duey Marc | Insider | buy | $1.17 | 21,459 | 256,155 | $25K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 2 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moAPRE contract awards, year to date.
Public federal awards linked to this ticker.
APRE lobbying filings, year to date.
Registered lobbying filings matched to Aprea Therapeutics Inc.